Proteins linked to immunotherapy resistance in colorectal cancer

Mayo Clinic researchers have identified two proteins, fibronectin and smooth muscle actin, linked to resistance to immunotherapy in metastatic colorectal cancer. This finding may explain why many patients do not respond to this treatment. Using advanced digital spatial profiling, the team analyzed protein expression in tumor tissues. They focused on the tumor's invasive margin, revealing how these proteins interact with cancer cells and the immune system. The study suggests that cancer-associated fibroblasts produce these proteins, which may suppress the immune response against tumors. This discovery could lead to more personalized treatment options for colorectal cancer patients.